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Introduction
Hodgkin's lymphoma is a B-cell neoplasm characterized by a minority of neoplastic cells within an extensive infiltrate of reactive cells. There is a classical form and a nodular lymphocyte predominant variant. The tumor cells in classical Hodgkin's lymphoma (cHL), the so-called Hodgkin and Reed-Sternberg (HRS) cells, are derived from pre-apoptotic germinal center B cells that acquire crippling immunoglobulin gene mutations and/or lose their capacity to express a high affinity B-cell receptor.
1 Epstein-Barr virus (EBV) infection, constitutive activation of nuclear factor kB and aberrant activation of receptor tyrosine kinases contribute to the survival and proliferation of HRS cells. 2, 3 The prognosis of cHL patients improved greatly over the last three decades and current treatment regimens have reduced treatment failure to less than 20% even in advanced stages. 4 However, long-term toxicities and especially secondary malignancies are major concerns and the main challenge in cHL is to avoid overtreatment in individual patients. The Ann Arbor staging system is used to classify cHL into early or advanced stage disease and treatment is tailored accordingly. In addition, several other clinicopathological factors are used for risk stratification. 5 Although some prognostic tissue markers, such as number of tumor-infiltrating macrophages, 6 HLA class II expression by tumor cells 7 and tumor cell EBV status, 8 have been published, there is currently no pre-treatment cHL prognostic factor that is applied for prediction of treatment response in a clinical setting.
The hepatocyte growth factor (HGF)/c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. 9 Deregulated cMet activation, caused by gene amplification, translocation, mutation or autocrine/paracrine HGF signaling, has been implicated in the pathogenesis of many human cancers. 10 Furthermore, c-Met is of prognostic significance in numerous malignancies, such as diffuse large B-cell lymphoma, 11 bladder cancer, 12 breast cancer, 13 colorectal cancer 14 and ovarian cancer. 15 Inhibitors have been developed to target this signaling pathway and one of these, SU11274, 16 shows effective inhibition of the c-Met signaling pathway, thereby affecting the survival and growth of lung cancer, 17 mesothelioma, 18 and melanoma 19 cell lines. c-Met expression has been reported in HRS cells in tissue samples from 33% (6/18) 20 and 100% (n=57) 21 of cHL patients. HGF expression was observed in infiltrating cells, especially in dendritic cells, but not in tumor cells. 21 Additionally, both c-Met and HGF are expressed in some cHL cell lines. 22, 23 We studied the function of the HGF/cMet pathway in cHL cell lines and determined the prognostic value of c-Met expression in two independent cohorts of patients. 
Design and Methods
Patients and tissue data
Immunohistochemistry
Immunohistochemistry (IHC) was performed with antibodies against c-Met (C-28) (Santa Cruz Biotechnology, Santa Cruz, CA, Table 1 . Basic characteristics of the German, Dutch and total combined cohorts of patients. The P value refers to the difference between the German and the Dutch patients.
Characteristic
All (n = 153) German (n = 91) Dutch (n=62) P value N. of patients (%) N. of patients (%) N. of patients (%) 
Cell lines
The cHL cell lines L428, L1236, KMH2 24 and U-HO1 25 were cultured in RPMI-1640 medium supplemented with ultraglutamine-1, 100 U/mL penicillin/streptomycin and 10% fetal calf serum (5% for the L428 cell line) (Lonza Walkersville, Walkersville, MD, USA).
Enzyme-linked immunosorbent assay on the supernatant of cultures of classical Hodgkin's lymphoma cell lines
Levels of HGF protein were measured in cell culture supernatants by an enzyme-linked immunosorbent assay according to the protocol provided by the manufacturer (R&D Systems).
Quantitative reverse transcriptase polymerase chain reaction
RNA was extracted using Trizol ® (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. cDNA was made from 500 ng of total RNA in 20 mL reactions using Superscript II and random primers (Invitrogen). Two nanograms of cDNA were used in the quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in triplicate using Sybergreen (for HGF) and probe (for U6), as described by the manufacturer (Applied Biosystems, Foster City, CA, USA). The primer sequences used for the amplification were as follows: U6 forward primer: 5'-ttcggcagcacatatactaa-3' and reverse primer 5'-aatatggaacgcttcacgaa-3'; U6 probe: 5'-ccctgcgcaaggatgaca-3', HGF forward primer (exon 5): 5'-caatccagaggtacgctacgaa-3' and reverse primer (exon 6) 5'-actctccccattgcaggtcat-3'. U6 was used for normalization (ΔCt = CtHGFCtU6). Relative expression levels of HGF were determined using the formula 2 -ΔCt .
Western blot
Cell lysates were separated on polyacrylamide gels and electroblotted onto nitrocellulose membranes using standard protocols. Blots were incubated with primary antibodies, c-Met (C12, Santa Cruz), p-Met (Tyr1234/1235), p-p44/42 MAPK (Thr202/Tyr204) (20G11), and p-Akt (Ser473) (D9E) (Cell Signaling Technology, Boston MA, USA), at 4ºC overnight. Immunostaining was amplified by incubation with horseradish peroxidase-conjugated antibodies and chemiluminescence was detected with ECL (Pierce, Rockford, USA).
MTT assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich) was added to cells and incubated for 4 h at 37°C. The cells were resolved in dimethylsulfoxide (Sigma Aldrich) and absorption was measured at 540 nm.
Cell cycle analysis
Hypotonic DNA staining buffer (0.1% sodium citrate; 0.3% Triton-X 100; 0.01% propidium iodide, 0.002% ribonuclease A) was added to the cells and mixed well. Data were acquired with a flow cytometer (Calibur, BD Biosciences, San Jose, CA, USA).
Definition of endpoints
Freedom from tumor progression (FFTP), and overall survival were the end-points for this study. FFTP was calculated from the date of diagnosis until the date of a disease-related event. Diseaserelated events were defined as progression during treatment, death during treatment with unknown disease status, less than a complete remission after treatment and relapse after treatment, including death due to lymphoma progression. In case none of these events occurred, patients were censored at the date of last followup or death. Overall survival was defined as the date of diagnosis until date of death. In the case of no events, patients were censored at the date of last follow-up.
Statistical analysis
Fisher's exact test was used for the analysis of differences in patients' characteristics between the German and Dutch cohorts of patients and between the c-Met-positive and c-Met-negative patients. Survival curves were computed using the method of Kaplan and Meier. Differences between the curves were calculated using the log-rank statistic. Univariate and multivariate Cox logistic regression models were applied to identify prognostic factors for survival. SPSS statistical software version 18.0 (SPSS Inc., Chicago, IL, USA) was used.
Results
c-Met and hepatocyte growth factor expression in chronic Hodgkin's lymphoma tissue
Cytoplasmic and membranous c-Met expression in more than 30% of the tumor cells was observed in 49 out of 91 German patients (54%) and 31 out of 62 Dutch patients (50%) ( Figure 1A and Online Supplementary Table S1). Expression was not significantly different between the two cohorts. Although c-Met expression could be detected in the reactive cellular background, no specific pattern of c-Met expression was observed between tumor cells and infiltrating cells.
HGF staining in more than 20% of the tumor cells was detected in 6 out 91 German patients (7%) and 4 out of 30 Dutch patients (13%) ( Figure 1B and Online Supplementary 
Prognostic significance of c-Met expression
In both the German and the Dutch cohorts, c-Metpositive patients had a significantly more favorable 5-year FFTP compared to c-Met-negative patients (Figure 2A,B) .
Univariate Cox regression analysis in the German cohort showed that lack of c-Met expression correlated with a hazard ratio (HR) of 4.2 (P=0.013, 95% CI 1.4-13.2), and stage with a HR of 4.6 (P=0.008, 95% CI 1.5-14.4). In multivariate analysis both stage (HR 4.5, P=0.010, 95% CI 1.4-13.9) and c-Met (HR 3.9, P=0.018, 95% CI 1.3-12.3) remained independent predictors for FFTP. In the Dutch c-Met expression predicts a favorable outcome in cHL haematologica | 2012; 97 (4) 575 Supplementary Table S3 ). In the combined cohort, cMet expression correlated with a 5-year FFTP of 94%, whereas no expression correlated with a 5-year FFTP of 73% (log rank P<0.001, Figure 2C ). Univariate Cox regression analysis showed that lack of c-Met expression correlated with a HR of 5.1 (P<0.001, 95% CI 1.9-13.5) compared to positive expression (Table 2) . Stage was the only other factor (HR 2.8, P=0.012) that could significantly predict FFTP. In multivariate analysis both c-Met (HR 5.0, P<0.001) and stage (HR 2.8, P=0.014) remained independent predictors for FFTP. Especially in patients with advanced disease, lack of c-Met expression correlated with a very poor 5-year FFTP rate (57% versus 91% in cMet-positive patients; Figure 2E, F) .
In the combined cohort, 5-year overall survival rates were 98% and 84% for patients expressing or not expressing c-Met, respectively (log rank P=0.006, Figure 2D ). For HGF, no significant differences were observed in FFTP and overall survival.
The c-Met/hepatocyte growth factor signaling pathway in classical Hodgkin's lymphoma cell lines
High c-Met expression was only observed in the L428 cell line ( Figure 3A) . HGF protein levels were high in the cell culture supernatant of KMH2, with corresponding levels of HGF mRNA ( Figure 3B, C) .
Phosphorylated c-Met (p-Met) was present only in the L428 cell line and stimulation by HGF strongly increased p-Met levels in this cell line. Low levels of p-Met were induced in L1236 and U-HO1 ( Figure 3D ). Analysis of pMet downstream substrates in the L428 cell line showed up-regulation of p-Akt and p-Erk1/2 upon HGF stimulation and this up-regulation was effectively blocked by SU11274 in a dose-dependent manner ( Figure 3E ). HGF stimulation did not affect cell growth (data not shown), whereas SU11274 significantly suppressed cell growth in a dose-dependent manner ( Figure 3F ). This suppression of cell growth was not caused by an induction of apoptosis (data not shown). Cell cycle analysis showed that the proportion of cells in the G2/M phase increased from 15% in control cells to 52% in cells treated with SU11274 (2.5 mM) (P<0.05) ( Figure 3G ). This effect was greater at a higher concentration (5 mM) (data not shown) or after longer incubation (48 h or 72 h) ( Figure 3G ), indicating dose-and time-dependent effects. After 48 h and 72 h a population of tetraploid cells appeared ( Figure 3G ).
Discussion
Deregulation of HGF/c-Met signaling has been implicated in the pathogenesis of many malignancies by disrupting fundamental biological processes including cell cycle, survival, adhesion and migration. 20, 26 In this study, we demonstrated that c-Met was present in HRS cells in half of the patients with cHL. In contrast to findings in other malignancies, [11] [12] [13] [14] [15] positivity of c-Met in the HRS cells was associated with favorable survival in two different cohorts of patients. Especially in advanced stage disease, c-Metpositive patients had a strikingly good FFTP rate (91%) compared to c-Met-negative patients (57%). This effect on prognosis appeared to be stronger than the effects that have been observed for other prognostic tissue markers such as CD68 (tumor infiltrating macrophages), 6 HLA class II 7 and EBV status. 8 Expression of c-Met and HGF has been studied previously in cHL patients and cell lines. [20] [21] [22] [23] One study showed a correlation between c-Met expression and EBV-positivity in a small cohort, 20 whereas in a larger study c-Met was detected in HRS cells of all cHL cases independently of EBV status. 21 We found c-Met expression in more than 30% of HRS cells in 52% of cHL cases and observed no correlation with EBV status. The lower percentage of c-Met-positive cHL cases can be explained by our strict scoring criteria compared to those used in previous studies. HGF expression was found in infiltrating cells in cHL tissues, and was higher in the serum of patients at diagnosis and at relapse than in the serum of healthy donors and patients in remission. 21 In our study, HGF expression was detected in HRS cells in a low percentage of cHL cases and in a variable percentage of the infiltrating cells in all cases. Co-expression of HGF and c-Met in HRS cells was found in only 3% of cHL patients. Paracrine activation of c-Met by HGF might be involved in the pathogenesis of cHL in c-Met-positive cases.
In contrast to our findings, in solid malignancies expression of c-Met correlates with an unfavorable prognosis. [12] [13] [14] [15] However, this involves overexpression rather than normal physiological expression and we found no evidence of overexpression of c-Met in Hodgkin's lymphoma. Although a favorable prognostic impact of c-Met expression has been shown in a small study on breast cancer 27 and in diffuse large B-cell lymphoma, 28 other studies showed opposite effects for both types of tumors. 11, 13 To explain the unexpected favorable prognostic impact of c-Met expression, we studied the functionality of the c-
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haematologica | 2012; 97(4) Met/HGF signaling pathway in the cHL cell line L428. Although p-Met, p-Akt and p-Erk1/2 are strongly up-regulated upon stimulation with HGF, no effect was observed on cell growth in L428 cells. Nevertheless we did observe an inhibitory effect on cell growth with c-Met inhibitor SU11274, which blocked the constitutive phosphorylation of c-Met and downstream kinases and induced G2/M cell cycle arrest. The stimulating effects of c-Met on cell cycle progression in L428 cells are inconsistent with the favorable prognostic value of c-Met positivity in HRS cells in cHL patients. The unique histological phenotype of cHL might be a key factor in this unexpected positive prognostic effect. The proportion of tumor cells in cHL is small, typically less than 1%, and these cells are located within an extensive infiltrate of reactive cells. In comparison, the proportion of tumor cells in diffuse large B-cell lymphoma and solid malignancies is generally between 40% and 80%. When focusing on the infiltrating cells several known effects of c-Met might explain the favorable effect of c-Met in Hodgkin's lymphoma. In a rat model of cirrhosis c-Met strongly reduced liver fibrosis and decreased transforming growth factor-β (TGF-β) levels. 29 Since TGF-β plays an important role in suppression of an effective immune response in cHL, 30 the activation of c-Met in HRS cells could result in decreased TGF-β production and, thereby, in enhanced anti-tumor responses. In monocytes, activation of c-Met induced upregulation of pro-inflammatory cytokines 31 and a proinflammatory response of the HGF/c-Met pathway was also found in experimental autoimmune encephalomyelitis. 32 Overall, it can be speculated that activation of c-Met in HRS cells might alter the immunosuppressive properties of the reactive cells by secretion of certain factors that shape the microenvironment in a way that c-Met expression predicts a favorable outcome in cHL haematologica | 2012; 97 (4) 577 
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